A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors

Participation Deadline: 12/31/2028
Apply Now

Description

This is a first-in-human Phase Ia/Ib, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and maximum tolerated dose (MTD) or maximum adminstered dose (MAD) of BPT567 in patients with advanced solid tumors, and establish the recommended dose for expansion cohorts.